CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

NasoVAXWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1146 ID NOW vs. Accula Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.

NCT04442230 Coronavirus Infection Biological: NasoVAX Other: Placebo
MeSH:Communicable Diseases Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Decrease from baseline in mean resting SpO2

Measure: Proportion of patients with clinical worsening

Time: Day 1 to Day 14

Secondary Outcomes

Description: Proportion of patients requiring hospitalization

Measure: Maximal severity of COVID-19 after treatment

Time: Day 1 to Day 42

Measure: All-cause mortality

Time: Day 1 to Day 42

No related HPO nodes (Using clinical trials)